Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
1.670
-0.075 (-4.30%)
At close: Oct 15, 2026, 4:00 PM EDT
1.700
+0.030 (1.80%)
After-hours: Oct 15, 2026, 7:36 PM EDT
Acumen Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
61
Market Cap
120.77M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Atrium Therapeutics | 35.84M |
| Voyager Therapeutics | 34.46M |
| Innate Pharma | 11.21M |
| Armata Pharmaceuticals | 5.54M |
| Korro Bio | 2.38M |
| Molecular Partners AG | 856.30K |
| Outlook Therapeutics | -1.16M |
ABOS News
- 4 weeks ago - Acumen Pharmaceuticals Transcript: Investor Day 2026 - Transcripts
- 4 weeks ago - Acumen Pharmaceuticals Slides: FY 2026 - Filings
- 4 weeks ago - Citi ups Acumen target, opens ‘upside 90-day catalyst watch’ - TheFly
- 5 weeks ago - Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026 - GlobeNewsWire
- 5 weeks ago - Acumen Pharmaceuticals Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts
- 5 weeks ago - Acumen Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 6 weeks ago - Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Acumen Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts